Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
36.92
+0.60 (1.65%)
At close: May 24, 2024, 4:00 PM
36.17
-0.75 (-2.03%)
After-hours: May 24, 2024, 7:30 PM EDT

Celldex Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 1994
Revenue
6.882.364.657.423.57
Upgrade
Revenue Growth (YoY)
192.02%-49.32%-37.30%107.61%-62.54%
Upgrade
Gross Profit
6.882.364.657.423.57
Upgrade
Selling, General & Admin
30.9127.220.4914.4615.43
Upgrade
Research & Development
118.0182.2653.3142.5342.67
Upgrade
Other Operating Expenses
12.5153.5181.8
Upgrade
Operating Expenses
161.43124.4577.374.9959.9
Upgrade
Operating Income
-154.54-122.1-72.65-67.57-56.33
Upgrade
Other Expense / Income
-13.11-9.77-1.91-6.63-5.45
Upgrade
Pretax Income
-141.43-112.33-70.74-60.95-50.88
Upgrade
Income Tax
00-0.23-1.170
Upgrade
Net Income
-141.43-112.33-70.51-59.78-50.88
Upgrade
Shares Outstanding (Basic)
4847433015
Upgrade
Shares Outstanding (Diluted)
4847433015
Upgrade
Shares Change
3.33%9.37%44.64%104.32%38.93%
Upgrade
EPS (Basic)
-2.92-2.40-1.64-2.02-3.51
Upgrade
EPS (Diluted)
-2.92-2.40-1.64-2.02-3.51
Upgrade
Free Cash Flow
-109.11-105.49-62.13-41.9-47.13
Upgrade
Free Cash Flow Per Share
-2.25-2.25-1.45-1.41-3.25
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-2245.27%-5180.14%-1561.99%-910.92%-1576.41%
Upgrade
Profit Margin
-2054.76%-4765.59%-1516.04%-805.88%-1423.96%
Upgrade
Free Cash Flow Margin
-1585.20%-4475.65%-1335.86%-564.86%-1318.95%
Upgrade
EBITDA
-138.42-109.43-67.67-57.02-46.02
Upgrade
EBITDA Margin
-2011.06%-4642.72%-1454.96%-768.64%-1287.99%
Upgrade
Depreciation & Amortization
3.012.93.073.934.86
Upgrade
EBIT
-141.43-112.33-70.74-60.95-50.88
Upgrade
EBIT Margin
-2054.76%-4765.59%-1520.92%-821.61%-1423.96%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).